RA
MGX icon

Resolute Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Resolute Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Hold
89,944
– – 0.05% 78
2025
Q4 		$146K Hold
89,944
– – 0.05% 70
2025
Q3 		$213K Hold
89,944
– – 0.05% 66
2025
Q2 		$133K Hold
89,944
– – 0.03% 66
2025
Q1 		$122K Hold
89,944
– – 0.04% 62
2024
Q4 		$325K Buy
89,944
+63,444
+239% +$153K 0.07% 51
2024
Q3 		$57.5K Hold
26,500
– – 0.01% 61
2024
Q2 		$108K Buy
26,500
+16,500
+165% +$113K 0.03% 53
2024
Q1 		$106K Buy
+10,000
New +$115K 0.02% 52

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Resolute Advisors's MGX Position: Q1 2026 in Review

Resolute Advisors held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 89,944 shares worth $121K. The position accounts for 0.05% of the portfolio, ranked #78.

Resolute Advisors first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $325K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Resolute Advisors held 89,944 shares of Metagenomi Therapeutics worth $121K as of Q1 2026.
  • Resolute Advisors left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up 0.05% of Resolute Advisors's portfolio in Q1 2026, its #78 holding.
  • Resolute Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Resolute Advisors's Metagenomi Therapeutics position peaked at $325K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Resolute Advisors's 13F filing for Q1 2026, filed 7 May 2026.